These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23252228)

  • 1. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 3. Fast track to 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Jan; 70(1):56-62. PubMed ID: 26863836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 6. The Reach of the 340B Drug Pricing Program.
    Albrecht J; Mudahar S
    JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384
    [No Abstract]   [Full Text] [Related]  

  • 7. Growing pains. Insurers and PbMs want in on 340B savings.
    Lee J
    Mod Healthc; 2012 Mar; 42(11):10. PubMed ID: 22462315
    [No Abstract]   [Full Text] [Related]  

  • 8. Pricing pain: relief in sight on drug costs?
    J Am Health Policy; 1992; 2(6):28-31. PubMed ID: 10122415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 10. Rx: Canadian drugs.
    Bugden S
    N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15014193
    [No Abstract]   [Full Text] [Related]  

  • 11. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 12. State and federal government mandates are changing the face of pharmacy management.
    Giaquinta D
    Manag Care Interface; 2001 May; 14(5):50-2. PubMed ID: 11385948
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
    Lewis JH; Schonlau M; Muñoz JA; Asch SM; Rosen MR; Yang H; Escarce JJ
    N Engl J Med; 2002 Mar; 346(11):830-5. PubMed ID: 11893795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: cost savings.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
    [No Abstract]   [Full Text] [Related]  

  • 17. 340B program presents opportunities--and challenges.
    Keough CL; Webster SA
    Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final notice regarding section 602 of the Veterans Health Care Act of 1992 duplicate discounts and rebates on drug purchases--HRSA. Final notice.
    Fed Regist; 1993 Jun; 58(119):34058-9. PubMed ID: 10126861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost consequences of the 340B drug discount program.
    Conti RM; Bach PB
    JAMA; 2013 May; 309(19):1995-6. PubMed ID: 23609758
    [No Abstract]   [Full Text] [Related]  

  • 20. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.